Brief: Lianbio Announces Mavacamten Granted Breakthrough Therapy Designation In China
15/02/2022 12:56
Feb 15 (Reuters) - LianBio LIAN.O :
* LIANBIO ANNOUNCES MAVACAMTEN GRANTED BREAKTHROUGH THERAPY
DESIGNATION IN CHINA
* LIANBIO- CENTER FOR DRUG EVALUATION (CDE) OF NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION GRANTED BREAKTHROUGH THERAPY DESIGNATION
IN CHINA FOR MAVACAMTEN
Source text for Eikon: ID:nGNX36YGqX
Further company coverage: LIAN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review